ReviewThe World Allergy Organization journal2017
Severe asthma and quality of life.
Review in The World Allergy Organization journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05078021 (Phenotyping Disease Severity in Asthma), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phenotyping Disease Severity in Asthma: Molecular Investigations of Corticosteroid
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- The efficacy and safety of biologics for patients with severe asthma: an umbrella review of systematic reviews and meta-analyses.Frontiers in medicine · 2025Pooled it
- Pharmacist Led Intervention on Inhalation Technique among Asthmatic Patients for Improving Quality of Life in a Private Hospital of Nepal.Pulmonary medicine · 2019Trial
- Psychometric properties of the Arabic IMPACT Bowel Function Short Form for assessing pelvic floor dysfunctions symptoms.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- A Pragmatic RCT of FF/UMEC/VI in Patients with Uncontrolled Asthma: PERFORM Protocol.Pulmonary therapy · 2026Article
- A data-driven approach to stock inhaler programming implementation in Chicago Public Schools.Discover public health · 2026Article
- Development, content validation and piloting of a questionnaire on how midwives in Germany provide advice on early childhood allergy prevention in a health literacy responsive way.European journal of midwifery · 2026Article
- Association between asthma control and health-related quality of life in severe asthma: a cross-sectional study from KoSAR.ERJ open research · 2025Article
- Article
- Trade-offs from a family perspective: considerations in choosing between omalizumab and complementary alternative medicine for pediatric severe asthma.Frontiers in pharmacology · 2025Review
- Real world evidence of dupilumab effectiveness in a Colombian cohort of patients diagnosed with severe asthma.Frontiers in allergy · 2025Article
- Article
- Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR.Allergy, asthma & immunology research · 2024Article
- The burden of severe asthma in sub-Saharan Africa: Findings from the African Severe Asthma Project.The journal of allergy and clinical immunology. Global · 2024Article
- Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK.NPJ primary care respiratory medicine · 2024Article
- Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma.Advances in therapy · 2024Article
- Birthing parent adverse childhood experiences and risk of atopic diseases in 5-year-old children.Frontiers in allergy · 2024Article
- Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry.Journal of asthma and allergy · 2024Article
- Health-related quality of life in severe hypersensitivity reactions: focus on severe allergic asthma and hymenoptera venom anaphylaxis-a cross-sectional study.Frontiers in psychology · 2024Article
- Unanswered questions on the use of biologics in pediatric asthma.The World Allergy Organization journal · 2023Review
- Using the 6-min walk test to assess the clinical response to mepolizumab and conventional therapy in severe eosinophilic asthma.ERJ open research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma has a great impact on the quality of life (QOL) of patients and their families. The magnitude of this morbidity is affected by several personal factors including age. Appropriate asthma control and modifications of social roles and activities are expected to improve QOL. Biologics, primarily monoclonal antibodies, have been developed to target specific pathways and molecules important in the pathogenesis of asthma. The use of biologics has shown some promising effects on the QOL of patients with severe recalcitrant asthma. Other potential measures involve targeting risk factors and comorbidities and improving the levels of adherence to therapy. This article briefly reviews the impact of severe asthma on QOL and the potential methods to combat this morbidity including the available therapeutic biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.